PARP-1 Signaling in DNA Damage and Cell Death
PARP-1 Signaling in DNA Damage and Cell Death
批准号:
9753761
负责人:
Yingfei Wang
金额:
$40.5万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-14 至 2022-07-31
关键词:
Alkylating AgentsCaspaseCell DeathCell NucleusCell SurvivalCessation of lifeCleaved cellClinicDNADNA DamageDNA RepairDevelopmentEnvironmentGeneticGenomic DNAGlutamatesGoalsInflammatoryInjuryKnowledgeLeadMalignant NeoplasmsMigration Inhibitory FactorMitochondriaMolecularMyocardial InfarctionNeurodegenerative DisordersNeurologicNeuronsOxidative StressPharmacologyPlayPoly Adenosine Diphosphate RibosePoly(ADP-ribose) PolymerasesProcessReactive Oxygen SpeciesReperfusion InjuryRoleSignal TransductionStrokeToxic effectWorkapoptosis inducing factorbody systemcancer cellcancer therapycell typechemotherapyclinical applicationexcitotoxicityhuman diseaseinhibitor/antagonistneoplastic cellneuron lossnovelnovel therapeuticsnucleasepost strokepreventrelease factorresponsetreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project summary
Poly(ADP-ribose) (PAR) polymerase-1 (PARP-1) plays a pivotal role in DNA damage response. It can be
activated either by the DNA alkylating agents abundant in our environment, or the byproducts of the cellular
oxidative stress or toxicity. In response to mild DNA damage, PARP-1 facilitates DNA repair process. Blockage
of PARP-1 activity sensitizes cancer cells to death. This concept is well supported by PARP inhibitor olaparib
used in clinic for cancer therapy. In contrast, in response to severe DNA damage, excessive activation of
PARP-1 causes the large DNA fragments and caspase-independent cell death designated parthanatos, which
occurs in many organ systems and is widely involved in different neurologic and non-neurologic diseases,
including ischemia-reperfusion injury after stroke and myocardial infarction, glutamate excitotoxicity,
neurodegenerative diseases, inflammatory injury, reactive oxygen species–induced injury. This type of cell
death is profoundly prevented by pharmacological inhibition or genetic deletion of PARP-1. The importance of
PARP-1 in cell death has also been appreciated in the cancer field as alkylating agents have been used in
chemotherapy to kill cancer cells. Therefore, these PARP-1 studies raise a huge knowledge gap how PARP-1
signaling is regulated in DNA damage or oxidative stress, leading to either DNA repair/cell survival or DNA
damage/cell death. Previous works from the PI have revealed the molecular mechanisms by which PAR
triggers apoptosis inducing factor (AIF) release from the mitochondria and translocation to the nucleus, leading
to PARP-1 dependent cell death (parthanatos). Recently PI further made an important discovery by identifying
macrophage migration inhibitory factor (MIF) as a novel nuclease and an executioner in parthanatos, which
cleaves genomic DNA into large fragments and causes neuron and cancer cell death. However, many
fundamental questions, including 1) how MIF nuclease activity is regulated in response to DNA damage and
oxidative stress in neurons and cancer cells; 2) how PARP-1 signaling in DNA damage is regulated and
switched between cell death and cell survival in neurons and cancer cells; 3) how to effectively interfere PARP-
1 signaling in DNA damage to prevent excess neuron loss but enhance cancer cell death, have not yet been
answered. The goals of this MIRA project are to obtain a comprehensive molecular understanding of PARP-1
signaling in DNA damage and to discover how PARP-1 signaling can be manipulated in response to mild or
severe DNA damage thereby preventing neuronal cell death but enhancing tumor cell death. If successful, the
knowledge achieved from these studies will directly impact the clinical application of PARP inhibitors for
treatment of cancer or stroke. Moreover, the comprehensive understanding of the regulatory networks of
PARP-1 signaling may also lead to the development of novel therapeutic strategies for the treatment of human
diseases caused by PARP-1 activation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of KDM6B in Alzheimer’s disease related dementia
-
批准号:10739281
-
项目类别:
-
资助金额:$74.95万
-
财政年份:2023
-
负责人:Yingfei Wang
-
依托单位:
The role of AIF3 in neurodegeneration of Alzheimer's disease
-
批准号:10190767
-
项目类别:
-
资助金额:$56.9万
-
财政年份:2019
-
负责人:Yingfei Wang
-
依托单位:
The role of AIF3 in neurodegeneration of Alzheimer's disease
-
批准号:10626004
-
项目类别:
-
资助金额:$56.94万
-
财政年份:2019
-
负责人:Yingfei Wang
-
依托单位:
The role of AIF3 in neurodegeneration of Alzheimer's disease
-
批准号:10434704
-
项目类别:
-
资助金额:$56.94万
-
财政年份:2019
-
负责人:Yingfei Wang
-
依托单位:
The role of AIF3 in neurodegeneration of Alzheimer's disease
-
批准号:10017857
-
项目类别:
-
资助金额:$56.73万
-
财政年份:2019
-
负责人:Yingfei Wang
-
依托单位:
PARP-1 Signaling in DNA Damage and Cell Death
-
批准号:10224826
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2017
-
负责人:Yingfei Wang
-
依托单位:
The role of a novel AIF-associated nuclease PAAN1 in neuronal injury
-
批准号:9197695
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2012
-
负责人:Yingfei Wang
-
依托单位:
The role of a novel AIF-associated nuclease PAAN1 in neuronal injury
-
批准号:8986742
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2012
-
负责人:Yingfei Wang
-
依托单位:
The role of a novel AIF-associated nuclease PAAN1 in neuronal injury
-
批准号:8545914
-
项目类别:
-
资助金额:$9.48万
-
财政年份:2012
-
负责人:Yingfei Wang
-
依托单位:
The role of a novel AIF-associated nuclease PAAN1 in neuronal injury
-
批准号:8441224
-
项目类别:
-
资助金额:$9.48万
-
财政年份:2012
-
负责人:Yingfei Wang
-
依托单位:
国内基金
海外基金
登录
查看更多内容
中药活性成分土木香内酯靶向 TXNL2 通过caspase-3/GSDME 介导的细胞焦亡抗未分化甲状腺癌的机制研究
-
批准号:ZCLQN26H2801
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:温庆良
-
依托单位:
壮骨止痛胶囊通过NLRP3/Caspase-1/GSDMD信号通路调控神经肽介导PMOP大鼠脑-肠-骨轴的机制研究
-
批准号:2026JJ81070
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:陈沙
-
依托单位:
骨痹汤调控NLRP3/ASC/Caspase-1介导的细胞焦亡治疗膝骨关节炎的作用及机制研究
-
批准号:2026JJ80380
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:郑艳艳
-
依托单位:
TIRAP调控NLRP3/Caspase-1/GSDMD通路诱导KOA软骨细胞焦亡机制的研究
-
批准号:2026JJ81783
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:肖杰
-
依托单位:
FUNDC1介导的线粒体自噬通过ROS/NLRP3/Caspase-1调控PSD小胶质细胞焦亡的机制研究及中药干预
-
批准号:2026JJ82568
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:袁霞红
-
依托单位:
Caspase-6介导的NOL12酶切降解在脓毒症性肝损伤中调控巨噬细胞焦亡的机制研究
-
批准号:JCZRLH202600702
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
基于“脑肠同调”理论从NLRP3/Caspase-1/GSDMD炎症通路探讨逍遥散对肝郁脾虚型FD大鼠的作用机制
-
批准号:2026JJ80620
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:贺美燕
-
依托单位:
基于Caspase-1介导的焦亡探讨OSF癌变及加味丹玄口康纳米胶束干预机制
-
批准号:2026JJ81019
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:李群
-
依托单位:
西维来司他钠通过抑制内皮细胞STING/caspase-1信号改善脓毒症血管高通透性的机制研究
-
批准号:2026JJ80584
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:彭甜
-
依托单位:
Prdx1通过Cathepsin B激活NLRP3/Caspase-1/GSDMD途径诱导结直肠癌细胞焦亡的作用机制研究
-
批准号:2025JJ60797
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:何影
-
依托单位: